NCT01491841 - IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

November 22, 2016

Study Completion Date

February 17, 2017

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Bendamustine + Rituximab + Pixantrone

Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).

DRUG

Pegfilgrastim

6mg administered on Day 2 of each 21 day cycle

Trial Locations (1)

27705

Duke University Medical Center, Durham